COMMUNIQUÉS West-GlobeNewswire
-
Entera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program)
22/12/2025 -
OneMedNet CEO Aaron Green Issues Letter to Shareholders Highlighting 2025
22/12/2025 -
Omada Health to Participate in J.P. Morgan Healthcare Conference
22/12/2025 -
PeopleOne Health Selected by Orlando Regional REALTOR® Association to Deliver First-of-Its-Kind Healthcare Solution for Realtors
22/12/2025 -
MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit®-Wound Gel
22/12/2025 -
Wholeview Wellness Joins the Lumina Therapy Alliance, Expanding Access to In-Person Addiction-Focused Psychotherapy for Employees and Their Families
22/12/2025 -
Greenwich LifeSciences Provides Additional Updates on FLAMINGO-01 and Corporate Strategy
22/12/2025 -
Biosplice Therapeutics Announces First Patient Dosed in Investigator‑Initiated Phase 1 Clinical Trial of Cirtuvivint and Olaparib in BRCA/HRD Platinum‑Resistant Ovarian Cancer
22/12/2025 -
Abbisko Therapeutics’ CSF-1R Inhibitor Pimicotinib Approved by the China NMPA, Addressing the Treatment Gap for Tenosynovial Giant Cell Tumor
22/12/2025 -
Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved
22/12/2025 -
Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal
22/12/2025 -
Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
22/12/2025 -
Secura Bio Provides Corporate Update and Highlights Progress in its Phase 3 TERZO Study
22/12/2025 -
Tilray Brands to Announce Second Quarter Fiscal Year 2026 Financial Results on January 8, 2026
22/12/2025 -
FDA approves Roche’s Lunsumio VELO™ for subcutaneous use in relapsed or refractory follicular lymphoma
22/12/2025 -
Ipsen élargit son portefeuille de produits en développement précoce avec un conjugué anticorps-médicament innovant développé par Simcere Zaiming
22/12/2025 -
Ipsen expands early development pipeline with Simcere Zaiming’s innovative antibody drug conjugate
22/12/2025 -
Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma
22/12/2025 -
SAFE, PARRAIN DE LA XIIème CONFERENCE INTERNATIONALE MAMMI EN ITALIE
22/12/2025
Pages